[Fundamental study and clinical testing of human tumor clonogenic assay (HTCA)].
Through our retrospective analysis of HTCA and clinical effects as well as fundamental studies, the following results were obtained: In this retrospective study, HTCA for lung cancer showed a predictive accuracy of 71%, a true positive rate of 50% and a true negative rate of 77%. To obtain good predictive accuracy, HTCA should be modified to provide conditions comparable to those in vivo with regard to drug concentration and drug exposure time. More precise analysis of the pharmacokinetics of anticancer agents might yield methodological improvement. A decrease in the chemosensitivity spectrum in vitro was observed after chemotherapy. This might be related to evidence that patients with prior chemotherapy exhibited a poor response rate to chemotherapy. There were no active anticancer agents against specimens with aplating efficiency of more than 0.04%. More extensive prospective trials will be necessary to determine the clinical value of HTCA. HTCA could be a superior assay for detecting the anti-tumor activity of new agents and a useful method for in vitro phase II study.
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D003114:Colony-Forming Units Assay / Q000379:methods / Q000592:standards; D004353:Drug Evaluation, Preclinical; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D012189:Retrospective Studies; D014410:Tumor Stem Cell Assay / Q000379:methods / Q000592:standards
D000970:Antineoplastic Agents